Left ventricular alterations and end-stage renal disease

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Left ventricular (LV) changes, particularly LV hypertrophy (LVH), are highly prevalent in patients with chronic kidney disease and end-stage renal disease (ESRD).
• LV enlargement in ESRD is often linked to increased stroke and cardiac index, typically with preserved systolic function.
• The primary drivers are chronic volume/flow overload from factors like anemia, arteriovenous shunts, and fluid retention.

Purpose of the Study:

• To elucidate the multifactorial causes of left ventricular hypertrophy (LVH) in end-stage renal disease (ESRD) patients.
• To highlight the contribution of both hemodynamic and non-hemodynamic factors to cardiac structural changes in ESRD.
• To emphasize the importance of managing contributing factors for improved clinical outcomes.

Main Methods:

• Review of existing literature on cardiovascular changes in ESRD.
• Analysis of etiological factors contributing to LVH in the ESRD population.
• Identification of hemodynamic and non-hemodynamic pathways involved in cardiac remodeling.

Main Results:

• High prevalence of LVH in ESRD patients, often associated with volume/flow overload.
• Hypertension identified as a major contributor to LVH in ESRD.
• Non-hemodynamic factors including angiotensin II, parathyroid hormone, and catecholamines also implicated in LVH and fibrosis.

Conclusions:

• Preventing LVH and its complications in ESRD requires addressing underlying causes of flow and pressure overload.
• Correction of anemia is essential for mitigating LVH in ESRD patients.
• A comprehensive approach targeting multiple contributing factors is necessary to improve cardiovascular outcomes in ESRD.